Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 287-292

  Otty, Zulfiquer ^a,c   Skinner, Monika Buhrer ^d   Dass, Joshua ^b,c   Collins, Michael ^b,c   Mooi, Jennifer ^a   Thuraisingam, Kandeepan ^b   Sabesan, Sabe ^a,c  

^a Department of Medical Oncology ^*  (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c Schools of Medicine and Dentistry   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

Chemoradiation; Cisplatin; Head and neck cancer; retrospective; Survival

Indexed keywords

CISPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CENTER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIATION DERMATITIS; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80052196072     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01405.x     Document Type: Article

References (20)

1. Adelstein DJ, Li Y, Adams GL etal. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
2. Pignon JP, Maitre AL, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17, 346 patients. Radiother Oncol 2009; 92: 4-14.
3. Cooper JS, Pajak TF, Forastiere AA etal. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
4. Bernier J, Domenge C, Ozsahin M etal. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
5. Forastiere AA, Goepfert H, Maor M etal. concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
6. AL-Sarraf M, Pajak TF, Marcial VA etal. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study. Cancer 1987; 59: 259-65.
7. Jeremic B, Shibamoto Y, Stanisavlijevic B etal. Radiation therapy alone or with concurrent low-dose daily cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997; 43: 29-37.
8. Huguenin P, Beer KT, Allal A, Rufibach K etal. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4613-21.
9. Steinmann D, Cerny B, Karstens JH etal. Chemotherapy with weekly cisplatin in 103 head and neck cancer patients. Strahlenther Onkol 2009; 10: 682-8.
10. Ho KF, Swindell R, Brammer CV etal. Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008; 47: 1513-8.
11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology version 2. 2010. Head and Neck Cancers. [cited 17 May 2011 Available from.
12. Kim YS, Shin SS, Nam JH, Kim YT, Kim JH, EK C. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108: 195-200.
13. Chan ATC, Leung SF, Ngan RKC etal. Overall survival after concurrent cisplatin radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-9.
14. Medina JA, Rueda A, de Pasos AS, Contreras J etal. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 2006; 79: 34-8.
15. Marcial VA. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group Study 81-17. Cancer 1990; 66: 1861-8.
16. Bahl M, Siu LL, Pond GR etal. Tolerability of Intergroup 0099 (INT0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 2004; 60: 1127-36.
17. Ozols RF. Cisplatin dose intensity. Semin Oncol 1989; 16 (Suppl 6): 22-30.
18. Bonner JA, Harari PM, Giralt J etal. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
19. Posner MR, Hershock DM, Blajman CR etal. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15.
20. Ragin CC, Tajoli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-20.